PMID- 20445531
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20100520
IS  - 1532-6535 (Electronic)
IS  - 0009-9236 (Linking)
VI  - 87
IP  - 6
DP  - 2010 Jun
TI  - Safety and feasibility of autologous bone marrow cellular therapy in 
      relapsing-progressive multiple sclerosis.
PG  - 679-85
LID - 10.1038/clpt.2010.44 [doi]
AB  - In this phase I study, we assessed the safety and feasibility of intravenous, 
      autologous bone marrow (BM) cell therapy, without immunosuppressive 
      preconditioning, in six patients with clinically definite, relapsing-progressive 
      multiple sclerosis (MS). Assessment of efficacy was a secondary objective and 
      employed clinical disability rating scales, multimodal evoked potential (MMEP) 
      recordings, and magnetic resonance imaging (MRI) scans. Cells were harvested, 
      filtered and infused intravenously in a day-case procedure that was well 
      tolerated by patients and was not associated with any serious adverse events 
      (AEs). Over a period of 12 months after the therapy, clinical disability scores 
      showed either no change (Extended Disability Status Score, EDSS) or improvement 
      (MS impact scale-29, MSIS-29), and MMEPs showed neurophysiological improvement. 
      MRI scans did not show any significant changes over a post-therapy period of 3 
      months. The lack of serious adverse effects and the suggestion of a beneficial 
      effect in this small sample of patients with progressive disease justify 
      conducting a larger phase II/III study to make a fuller assessment of the 
      efficacy of mobilization of autologous BM in patients with MS.
FAU - Rice, C M
AU  - Rice CM
AD  - Institute of Clinical Neurosciences, University of Bristol, Frenchay Hospital, 
      Bristol, UK.
FAU - Mallam, E A
AU  - Mallam EA
FAU - Whone, A L
AU  - Whone AL
FAU - Walsh, P
AU  - Walsh P
FAU - Brooks, D J
AU  - Brooks DJ
FAU - Kane, N
AU  - Kane N
FAU - Butler, S R
AU  - Butler SR
FAU - Marks, D I
AU  - Marks DI
FAU - Scolding, N J
AU  - Scolding NJ
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100505
PL  - United States
TA  - Clin Pharmacol Ther
JT  - Clinical pharmacology and therapeutics
JID - 0372741
SB  - IM
MH  - Adult
MH  - Bone Marrow Transplantation/adverse effects/*methods
MH  - Disability Evaluation
MH  - *Evoked Potentials
MH  - Feasibility Studies
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Magnetic Resonance Imaging/*methods
MH  - Male
MH  - Middle Aged
MH  - Multiple Sclerosis, Relapsing-Remitting/*surgery
MH  - Prospective Studies
MH  - Transplantation, Autologous
EDAT- 2010/05/07 06:00
MHDA- 2010/06/04 06:00
CRDT- 2010/05/07 06:00
PHST- 2010/05/07 06:00 [entrez]
PHST- 2010/05/07 06:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
AID - clpt201044 [pii]
AID - 10.1038/clpt.2010.44 [doi]
PST - ppublish
SO  - Clin Pharmacol Ther. 2010 Jun;87(6):679-85. doi: 10.1038/clpt.2010.44. Epub 2010 
      May 5.